Loading...
About 10% of asthma patients continue to experience exacerbations despite using high-dose inhaled corticosteroids steroids (ICS) and long-acting β-agonists, and many patients require long-term oral corticosteroids (OCS). Research has focused on defining phenotypes (such as allergic, eosinophilic, and neutrophilic subtypes) for these hard-to-treat asthmatic patients. Mepolizumab is a humanized monoclonal antibody that binds to and inactivates interleukin-5, prevents exacerbations, and lowers OCS requirements in patients with severe eosinophilic asthma. In two industry-funded, placebo-controlled trials, researchers enrolled patients with severe eosinophilic asthma and serum eosinophil counts of ≥300 cells/μL during the 12 months before random…